Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis

V. Strmiska, P. Michalek, Z. Lackova, R. Guran, S. Krizkova, L. Vanickova, O. Zitka, M. Stiborova, T. Eckschlager, B. Klejdus, D. Pacik, E. Tvrdikova, C. Keil, H. Haase, V. Adam, Z. Heger,

. 2019 ; 13 (5) : 1002-1017. [pub] 20190309

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20022761

DNA hypermethylation is one of the most common epigenetic modifications in prostate cancer (PCa). Several studies have delineated sarcosine as a PCa oncometabolite that increases the migration of malignant prostate cells while decreasing their doubling time. Here, we show that incubation of prostate cells with sarcosine elicited the upregulation of sarcosine N-demethylation enzymes, sarcosine dehydrogenase and pipecolic acid oxidase. This process was accompanied by a considerable increase in the production of the major methyl-donor S-adenosylmethionine (SAMe), together with an elevation of cellular methylation potential. Global DNA methylation analyses revealed increases in methylated CpG islands in distinct prostate cell lines incubated with sarcosine, but not in cells of nonprostate origin. This phenomenon was further associated with marked upregulation of DNA methyltransferases (Dnmts). Epigenetic changes were recapitulated through blunting of Dnmts using the hypomethylating agent 5-azacytidine, which was able to inhibit sarcosine-induced migration of prostate cells. Moreover, spatial mapping revealed concomitant increases in sarcosine, SAMe and Dnmt1 in histologically confirmed malignant prostate tissue, but not in adjacent or nonmalignant tissue, which is in line with the obtained in vitro data. In summary, we show here for the first time that sarcosine acts as an epigenetic modifier of prostate cells and that this may contribute to its oncometabolic role.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022761
003      
CZ-PrNML
005      
20201214124752.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/1878-0261.12439 $2 doi
035    __
$a (PubMed)30628163
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Strmiska, Vladislav $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic.
245    10
$a Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis / $c V. Strmiska, P. Michalek, Z. Lackova, R. Guran, S. Krizkova, L. Vanickova, O. Zitka, M. Stiborova, T. Eckschlager, B. Klejdus, D. Pacik, E. Tvrdikova, C. Keil, H. Haase, V. Adam, Z. Heger,
520    9_
$a DNA hypermethylation is one of the most common epigenetic modifications in prostate cancer (PCa). Several studies have delineated sarcosine as a PCa oncometabolite that increases the migration of malignant prostate cells while decreasing their doubling time. Here, we show that incubation of prostate cells with sarcosine elicited the upregulation of sarcosine N-demethylation enzymes, sarcosine dehydrogenase and pipecolic acid oxidase. This process was accompanied by a considerable increase in the production of the major methyl-donor S-adenosylmethionine (SAMe), together with an elevation of cellular methylation potential. Global DNA methylation analyses revealed increases in methylated CpG islands in distinct prostate cell lines incubated with sarcosine, but not in cells of nonprostate origin. This phenomenon was further associated with marked upregulation of DNA methyltransferases (Dnmts). Epigenetic changes were recapitulated through blunting of Dnmts using the hypomethylating agent 5-azacytidine, which was able to inhibit sarcosine-induced migration of prostate cells. Moreover, spatial mapping revealed concomitant increases in sarcosine, SAMe and Dnmt1 in histologically confirmed malignant prostate tissue, but not in adjacent or nonmalignant tissue, which is in line with the obtained in vitro data. In summary, we show here for the first time that sarcosine acts as an epigenetic modifier of prostate cells and that this may contribute to its oncometabolic role.
650    _2
$a buněčné linie $7 D002460
650    12
$a CpG ostrůvky $7 D018899
650    _2
$a epigeneze genetická $x účinky léků $7 D044127
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prostata $x metabolismus $x patologie $7 D011467
650    _2
$a nádory prostaty $x metabolismus $x patologie $7 D011471
650    _2
$a sarkosin $x farmakologie $7 D012521
650    _2
$a upregulace $x účinky léků $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Michalek, Petr $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Lackova, Zuzana $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Guran, Roman $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Krizkova, Sona $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Vanickova, Lucie $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Zitka, Ondrej $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Prague 2, Czech Republic.
700    1_
$a Eckschlager, Tomas $u Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague 5, Czech Republic.
700    1_
$a Klejdus, Borivoj $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Mendel University in Brno, Czech Republic.
700    1_
$a Pacik, Dalibor $u Department of Urology, University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Tvrdikova, Eliska $u Department of Pathology, University Hospital Brno, Czech Republic.
700    1_
$a Keil, Claudia $u Department of Food Chemistry and Toxicology, Technical University of Berlin, Germany.
700    1_
$a Haase, Hajo $u Department of Food Chemistry and Toxicology, Technical University of Berlin, Germany.
700    1_
$a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
700    1_
$a Heger, Zbynek $u Department of Chemistry and Biochemistry, Mendel University in Brno, Czech Republic. Central European Institute of Technology, Brno University of Technology, Czech Republic.
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 13, č. 5 (2019), s. 1002-1017
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30628163 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124752 $b ABA008
999    __
$a ok $b bmc $g 1595080 $s 1113437
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 13 $c 5 $d 1002-1017 $e 20190309 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options